Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$40.67
52W Range
$8.24 - $44.80
50D Avg
$35.11
200D Avg
$18.76
Market Cap
$2.66B
Avg Vol (3M)
$1.63M
Beta
0.40
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.